secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001683168-23-005540
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma Q2 2023 revenues jump 3,600% YoY to $5.56M
-------------------------------------------------------------

- Revenues of $5,560,865 for Q2 2023, a 3,600% increase over Q2 2022.
- Revenue growth driven by Nora Pharma generic drug sales, acquired Oct 2022.
- Q2 2023 revenues up 13.6% sequentially from Q1 2023.
- CEO Dr. Steve Slilaty expressed optimism for continued growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/0001683168-23-005540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823005540/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer